Baxter

Baxter International, Inc. engages in the provision of a portfolio of essential renal and hospital products, including acute and chronic dialysis, sterile IV solutions, infusion systems and devices, parenteral nutrition therapies, premixed and oncolytic injectable, bio surgery products and anesthetics, drug reconstitution systems and pharmacy automation, software, and services. It operates through the following segment: Americas, Europe, Middle East and Africa (EMEA), Asia-Pacific (APAC), and Hillrom. The Americas, EMEA, and APAC segments offer a portfolio of essential healthcare products. The Hillrom segment provides digital and connected care solutions and collaboration tools, including smart bed systems, patient monitoring and diagnostic technologies, respiratory health devices and advanced equipment for the surgical space. The company was founded by Davis Baxter in 1931 and is headquartered in Deerfield, IL.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Baxter reports robust Q4 sales, eyes growth amid operational challenges

Baxter International's Q4 2022 performance reflects strong sales growth and strategic actions to enhance agility and market responsiveness.
While facing challenges such as lower-than-expected earnings and supply chain constraints, the company is focused on cost reduction and operational improvements.
Opportunities lie in R&D investments, cost synergies from the Hillrom integration, and improving backlog and backorders, positioning Baxter for future growth.
Analysts' concerns about operating margins and financial outlook for 2023 highlight the need for continued efficiency measures and strategic planning.

Baxter beats Q1 expectations, plans spin-off for strategic clarity

Baxter's Q1 performance exceeded expectations with sales growth in key segments and adjusted EPS surpassing guidance.
The company is progressing well with its strategic initiatives, including the spin-off of Renal Care and new operating model.
Challenges in legacy businesses and soft hospital spending highlight areas for improvement, while opportunities lie in new product launches and margin enhancement strategies.
Overall, Baxter's focus on innovation, operational efficiency, and market trends positions it for long-term success and growth.

Baxter exceeds Q2 expectations, eyes growth amid strategic actions

Baxter's Q2 2023 performance showcased resilience and adaptability in a dynamic healthcare market, with strategic actions underway to drive operational efficiency and growth.
The company's focus on innovation, safety, and market responsiveness positions it well for future success, despite challenges such as pending divestitures and market uncertainties.
With a strong performance, growth opportunities in key segments, and operational improvements driving margin expansion, Baxter is navigating challenges to capitalize on future growth prospects.

Baxter beats Q3 expectations, eyes growth through strategic initiatives

Baxter's Q3 2023 performance exceeded expectations, with a focus on strategic priorities and the upcoming Kidney Care segment separation.
The company's strengths lie in maintaining market share, operational efficiencies, and maximizing shareholder value through financial analysis.
Challenges include renegotiating contracts, rising energy costs, and achieving organic growth amidst market dynamics.
Opportunities for Baxter include growth through cost improvements, margin programs, and product launches in 2024.

Baxter surpasses Q4 expectations, eyes growth amid inflation challenges

Baxter's Q4 2023 performance exceeded expectations, driven by growth in key segments and strategic initiatives, setting the stage for continued success in 2024.
Despite challenges like inflation and flat growth in certain segments, Baxter's focus on margin improvement, debt management, and growth strategies positions the company for future resilience.
With a strong outlook for 2024, Baxter aims to capitalize on opportunities for growth, margin improvement, and market expansion, supported by a solid financial foundation and strategic priorities.

Baxter surpasses Q1 expectations with focus on innovation and growth

Baxter's Q1 2024 performance exceeded expectations, driven by strong sales growth and focus on innovation, despite challenges in certain segments and geographies.
The company's strategic strengths lie in diverse growth drivers, strong segment margins, and geographic expansion successes, positioning it for continued success.
Addressing challenges in underperforming segments and markets, along with seizing opportunities for improvement and expansion, will be crucial for Baxter's future growth.
With a clear focus on innovation, margin expansion, and shareholder value maximization, Baxter aims to navigate challenges and capitalize on growth prospects for sustained success.

Baxter exceeds Q2 expectations, plans Kidney Care separation for growth

Baxter International's Q2 2024 earnings call highlighted robust performance, strategic initiatives, and a positive outlook for sales growth and earnings per share.
The company's focus on margin improvement, innovation, and operational efficiency positions it well for sustained growth and shareholder value creation.
While facing challenges in certain segments and external factors, Baxter's proactive approach and strong fundamentals offer opportunities for future expansion and success.
Investors can look forward to Baxter's continued commitment to driving growth, expanding margins, and delivering innovative healthcare solutions.

Baxter reports solid Q3 performance amidst challenges and growth opportunities

Baxter International demonstrated resilience in Q3 2024 with sales growth and earnings exceeding expectations despite challenges.
The company's focus on operational efficiency, cost containment, and strategic divestitures positions it well for future growth.
Challenges from Hurricane Helene impact and Kidney Care separation are being addressed with a clear vision for sustained performance.
Opportunities for growth and margin expansion underscore Baxter's commitment to delivering value to shareholders and patients.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Baxter International, Inc. engages in the provision of a portfolio of essential healthcare products including acute and chronic dialysis therapies, sterile intravenous (IV) solutions, infusion systems and devices, parenteral nutrition therapies, inhaled anesthetics, generic injectable pharmaceuticals, surgical hemostat and sealant products, surgical equipment, smart bed systems, patient monitoring and diagnostic technologies, and respiratory health devices. It operates through the following segments: Americas, Europe, Middle East and Africa (EMEA), Asia-Pacific (APAC), and Hillrom. The Americas, EMEA, and APAC segments offer a portfolio of essential healthcare products. The Hillrom segment provides digital and connected care solutions and collaboration tools, including smart bed systems, patient monitoring and diagnostic technologies, respiratory health devices, and equipment for the surgical space. The company was founded by Davis Baxter in 1931 and is headquartered in Deerfield, IL.

Atlanta Braves Holdings Inc

Bruker

BATRA, BAX and BRKR have been added to the Zacks Rank #5 (Strong Sell) List on November 21, 2024.

New Strong Sell Stocks for November 21st

DEERFIELD, Ill.--(BUSINESS WIRE)--Baxter International Inc. (NYSE:BAX), a global medtech leader, will present at the 7th Annual Evercore HealthCONx Conference on Thursday, December 5, 2024. Joel Grade, Baxter's chief financial officer, is scheduled to present at 9:10 a.m. Eastern Time. The live webcast of Baxter's presentation can be accessed at www.baxter.com and will be available for replay through Tuesday, June 3, 2025. About Baxter Every day, millions of patients and caregivers rely on Baxt.

Baxter to Present at 7th Annual Evercore HealthCONx Conference

DEERFIELD, Ill.--(BUSINESS WIRE)--Baxter International Inc. (NYSE:BAX), a global medtech leader, will present at the Jefferies London Healthcare Conference on Wednesday, November 20, 2024. Joel Grade, Baxter's chief financial officer, is scheduled to present at 11:00 a.m. Greenwich Mean Time. The live webcast of Baxter's presentation can be accessed at www.baxter.com and will be available for replay through Monday, May 19, 2025. About Baxter Every day, millions of patients and caregivers rely o.

Baxter to Present at Jefferies London Healthcare Conference

DEERFIELD, Ill.--(BUSINESS WIRE)--Baxter International Inc. (NYSE:BAX), a global medtech leader, will present at the Stifel 2024 Healthcare Conference on Monday, November 18, 2024. Joel Grade, Baxter's chief financial officer, is scheduled to present at 8:35 a.m. Eastern Time. The live webcast of Baxter's presentation can be accessed at www.baxter.com and will be available for replay through Saturday, May 17, 2025. About Baxter Every day, millions of patients and caregivers rely on Baxter's lea.

Baxter to Present at Stifel 2024 Healthcare Conference

DEERFIELD, Ill.--(BUSINESS WIRE)--Baxter International Inc. (NYSE:BAX), a global medtech leader, today announced that its Board of Directors has declared a quarterly cash dividend of $0.17 per share of common stock. The dividend is payable on Jan. 2, 2025, to stockholders of record as of Nov. 29, 2024. The indicated annual dividend rate is $0.68 per share of common stock. This dividend represents the new quarterly dividend rate for Baxter in anticipation of the divestiture of its Kidney Care bu.

Baxter Declares Quarterly Dividend

Baxter International Inc. (NYSE:BAX ) Q3 2024 Earnings Conference Call November 8, 2024 8:30 AM ET Company Participants Clare Trachtman - Senior Vice President, Chief Investor Relations Officer Joe Almeida - Chairman, President and Chief Executive Officer Joel Grade - Executive Vice President and Chief Financial Officer Conference Call Participants Travis Steed - Bank of America Securities Robert Marcus - JPMorgan Pito Chickering - Deutsche Bank Vijay Kumar - Evercore ISI Joanne Wuensch - Citi Lawrence Biegelsen - Wells Fargo David Roman - Goldman Sachs Operator Good morning, ladies and gentlemen, and welcome to Baxter International's Third Quarter 2024 Earnings Conference Call. Your lines will remain in a listen-only mode until the question-and-answer segment of today's call.

Baxter International Inc. (BAX) Q3 2024 Earnings Call Transcript

Baxter reports better-than-expected third-quarter results. However, the company's gross and operating margins contract.

BAX Stock Falls Despite Q3 Earnings & Sales Beat, Margins Decline

Although the revenue and EPS for Baxter (BAX) give a sense of how its business performed in the quarter ended September 2024, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.

Baxter (BAX) Reports Q3 Earnings: What Key Metrics Have to Say

Baxter International (BAX) came out with quarterly earnings of $0.80 per share, beating the Zacks Consensus Estimate of $0.78 per share. This compares to earnings of $0.68 per share a year ago.

Baxter International (BAX) Beats Q3 Earnings Estimates

Baxter International cut its annual profit forecast on Friday due to a hurricane-related hit to its intravenous solutions facility, sending its shares down 3.3% in premarket trading.

Baxter cuts annual profit forecast on hurricane impact

DEERFIELD, Ill.--(BUSINESS WIRE)--Baxter International Inc. (NYSE:BAX), a global medtech leader, today reported results for the third quarter of 2024. “Baxter delivered positive performance in the third quarter of 2024, as the company continues to execute against its strategic transformation,” said José (Joe) E. Almeida, chair, president and chief executive officer. “The pending sale of our Kidney Care business represents another defining milestone in our ongoing transformation journey. We are.

Baxter Reports Third-Quarter 2024 Results

BAX's third-quarter results are likely to benefit from a positive pricing impact and new product launches. However, supply-chain issues are likely to have raised expenses in the quarter.

Strong Demand and Positive Pricing to Drive Baxter's Q3 Earnings

Evaluate the expected performance of Baxter (BAX) for the quarter ended September 2024, looking beyond the conventional Wall Street top-and-bottom-line estimates and examining some of its key metrics for better insight.

Countdown to Baxter (BAX) Q3 Earnings: A Look at Estimates Beyond Revenue and EPS

Medical device maker Baxter said on Thursday it has restarted the highest-throughput intravenous solutions manufacturing line at its North Carolina facility, which was impacted by hurricane-related flooding.

Baxter restarts IV solutions manufacturing line

DUBLIN--(BUSINESS WIRE)--Oneview Healthcare, a leading provider of patient experience solutions is pleased to announce the extension of its strategic relationship with Baxter International Inc. for an additional two years and expand the agreement to include Canada. Since the signing of the Value-Added Reseller Agreement in June 2023 for the US market, Oneview and Baxter have focused on sales enablement and operational readiness to enable Baxter to sell, quote, contract, and deliver Oneview to t.

Oneview Healthcare and Baxter International Extend Value-Added Reseller Agreement for Two More Years and Expand the Agreement to include Canada

Medical device maker Baxter said on Thursday it expects to restart the highest-throughput IV solutions manufacturing line at a hurricane-hit plant in North Carolina within the next week.

Baxter expects to restart IV solutions manufacturing line within next week

DEERFIELD, Ill.--(BUSINESS WIRE)--Baxter International Inc. (NYSE:BAX), a global medtech leader, will present at the UBS Global Healthcare Conference on Wednesday, November 13, 2024. Joel Grade, Baxter's chief financial officer, is scheduled to present at 1:15 p.m. Pacific Time. The live webcast of Baxter's presentation can be accessed at www.baxter.com and will be available for replay through Monday, May 12, 2025. About Baxter Every day, millions of patients and caregivers rely on Baxter's lea.

Baxter to Present at UBS Global Healthcare Conference

Baxter International on Monday said that it aims to restore the number of new patients able to begin using its peritoneal dialysis solutions to pre-Hurricane Helene levels by the end of the year.

Baxter aims to restore new dialysis patient access to pre-hurricane levels by year-end

LeMaitre Vascular

Investors looking for stocks in the Medical - Products sector might want to consider either Baxter International (BAX) or LeMaitre Vascular (LMAT). But which of these two companies is the best option for those looking for undervalued stocks?

BAX or LMAT: Which Is the Better Value Stock Right Now?

Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.

Should Value Investors Buy Baxter International (BAX) Stock?

Baxter International said on Thursday it will import 18,000 tons of intravenous products from its newly cleared international plants to the U.S. by the end of the year to mitigate a shortage caused by Hurricane Helene.

Baxter to import 18,000 tons of IV products to US by year-end

DEERFIELD, Ill.--(BUSINESS WIRE)--Baxter International Inc. (NYSE:BAX), a global medtech leader, will host a conference call to discuss its third-quarter 2024 financial results on Friday, November 8, 2024 at 7:30 a.m. Central Time. To participate in this conference call please follow this link https://events.q4inc.com/attendee/391655054 to pre-register for the call and receive the call information. This call is also being webcast and can be accessed through Baxter's website at www.baxter.com. T.

Baxter to Host Third-Quarter 2024 Financial Results Conference Call for Investors

The Federal Reserve's rate cut historically boosts healthcare stocks, and Baxter International's recent downturn presents a buying opportunity due to overblown market reactions. Baxter's acquisition of Hill-Rom and subsequent challenges, including rising input costs and supply chain issues, have been addressed, setting the stage for recovery. The sale of Baxter's kidney care business and debt repayment will strengthen the balance sheet, enabling future share repurchases and margin expansion.

Baxter Is A Strong Buy: The Turnaround Story You Can't Ignore

Baxter International Inc. (BAX, Financial), a leading healthcare company, has issued a press release detailing the impact of Hurricane Helene on its North Cove facility located in Marion, North Carolina. The hurricane brought unprecedented rain and extensive flooding to the region, resulting in the temporary closure of the facility for production as the company undertakes necessary remediation efforts.

Baxter International (BAX) Reports Impact of Hurricane Helene on North Cove Facility

BAX's robust growth across all regions, along with transformational initiatives, boosts confidence. However, pandemic-related disruption continues to hurt sales.

News for Baxter Stock (BAX)